Morepen Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹485Cr
- +4.1% YoY
- +0.2% QoQ
- Net profit
- ₹16Cr
- −20% YoY
- −42.9% QoQ
- Margin
- 5%
- −4 pp YoY
- −5 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Morepen Laboratories Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5). Q4 FY26 EBITDA: Rs. 33 crore, up 24% YoY (Page 12).
From Morepen Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5)
- API segment Q4 growth: 17% YoY (Page 5)
- Medical Devices segment Q4 growth: 31% YoY (Page 5)
- FY26 total revenue growth: 8% YoY, Rs. 597 crore reported (Page 10, 5)
- Gross revenue FY25: Rs. 1570 crore; FY26 forecast: Rs. 1703 crore, implying 8-9% growth (Page 13)
- Q4 FY26 EBITDA margin about 6.8%; FY26 EBITDA 10.8% (Page 12, 13)
- Outlook: Long-duration manufacturing programs started Q4 FY26 expected to progressively support operating leverage and growth (Pages 12, 13)
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).
- Focus on long-duration supply programs to improve operating leverage and stable recurring revenues.
- CDMO & Manufacturing: Audits and validation batches completed; commercial production commenced; phased delivery schedule received, starting Q4 FY26.
- Building 20% ‘ready capacity’ to onboard new customers and developing speciality portfolio for select clients.
- Status: Commercial supplies under long-duration manufacturing programs began in Q4 FY26.
2 more points from Morepen Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation reports that Morepen Laboratories Limited has secured a multi-year mandate worth Rs. 823 crore under its commercial program milestones (Page 3).
- It mentions that commercial production has commenced and phased delivery is scheduled to start in the coming weeks (Page 3).
- On Page 13, it is stated that Q4 FY26 marked the commencement of commercial supplies under long-duration manufacturing programs, indicating progress in order fulfillment.
- The focus is on the secured multi-year mandate, commencement of commercial production, and transition toward long-duration supply contracts with stable recurring revenues.
Morepen Laboratories Ltd — Quarterly revenue & net profit
Morepen Laboratories Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 485 | 466 | +4.1% | 484 | +0.2% |
| Operating profit (EBITDA) | 24 | 42 | -42.9% | 46 | -47.8% |
| Operating margin | 5% | 9% | -4 pp | 10% | -5 pp |
| Profit before tax | 23 | 26 | -11.5% | 35 | -34.3% |
| Net profit (PAT) | 16 | 20 | -20% | 28 | -42.9% |
| EPS (₹) | 0.29 | 0.37 | -21.6% | 0.50 | -42% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q4 FY26 results?
Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5). Q4 FY26 EBITDA: Rs. 33 crore, up 24% YoY (Page 12).
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
